available for iOS, Android and web
Pioneering approach to be funded under controlled conditions
Did not improve progression-free survival
Thirty years of development
Journal accused of biased agenda
Profits hit by currency impact
Also boosted by Abraxane
Living with multiple conditions 'now the norm'
A waste of time or way forward?
PharmaTimes 2014 Copyright | RSS Feed Subscriptions Software Development by DCSL Software